| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 12.81 | 28.1% | 5.4% |
| Total Income | 12.81 | 28.1% | 5.4% |
| Expenditure | 24.29 | 13.7% | 11.3% |
| PBT | -15.45 | 14.0% | 34.2% |
| Net Profit | -15.45 | 14.0% | 34.2% |
| OPM | -89.63% | 28.41pp | |
| NPM | — | ||
| EPS | -0.14 | 0.0% | 7.7% |
Aquestive Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:03 am
Summary
Aquestive Therapeutics announced its Q3 2025 financial results, with total revenues at $12.8 million. Excluding the impact of one-time deferred revenue recognition in the prior year, revenues increased by 4% year-over-year. The net loss for the quarter was $15.4 million, or $0.14 per share. The company is preparing for the potential U.S. launch of Anaphylm in Q1 2026, pending FDA approval, and continues to advance its global expansion strategy.
Key Highlights
- 1
Aquestive Therapeutics reported a 4% year-over-year increase in total revenues, excluding one-time deferred revenue recognition, reaching $12.8 million in Q3 2025.
- 2
Manufacture and supply revenue increased to $11.5 million in the third quarter of 2025, up from $10.7 million in the third quarter of 2024.
- 3
Research and development expenses decreased to $4.5 million in Q3 2025 from $5.3 million in Q3 2024, primarily due to lower clinical trial costs.
- 4
The company's net loss for the third quarter of 2025 was $15.4 million, or $0.14 loss per share.
- 5
Cash and cash equivalents were $129.1 million as of September 30, 2025.
- 6
The company anticipates a U.S. launch of Anaphylm in the first quarter of 2026, pending FDA approval.
- 7
Aquestive broadened its patent estate for Anaphylm with the issuance of two new patents extending protection into 2037.
Management Comments
Daniel Barber
“The third quarter was another period of strong execution for Aquestive as we move closer to the launch of Anaphylm, if approved by the FDA,” said Daniel Barber, Chief Executive Officer of Aquestive. “The FDA’s decision not to convene an Advisory Committee further advances our regulatory path, and our NDA remains on track for the scheduled January 31, 2026 PDUFA goal date. We are fully engaged in U.S. launch preparations, continuing to build commercial readiness across distribution, medical affairs, and marketing channels, while also advancing regulatory discussions in Canada and the EU. Following our recently completed equity financing and strategic funding commitments, we believe we are well positioned to deliver on our mission to make epinephrine emergency treatment more accessible, portable, and patient-friendly. Finally, we remain committed to developing additional products from our AdrenaVerse™ epinephrine prodrug platform.”
Informational and educational content only. Not investment advice.